PCM
URGN icon

Penserra Capital Management’s UroGen Pharma URGN Stock Holding History

Penserra Capital Management’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-510
Closed -$8K – 1556
2021
Q3 		$8K Hold
510
– – ﹤0.01% 1384
2021
Q2 		$7K Buy
510
+15
+3% +$271 ﹤0.01% 1299
2021
Q1 		$9K Sell
495
-10
-2% -$212 ﹤0.01% 1048
2020
Q4 		$9K Buy
505
+315
+166% +$6.6K ﹤0.01% 937
2020
Q3 		$3K Buy
+190
New +$4.3K ﹤0.01% 891

Other funds holding URGN

MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
HCM
Horton Capital Management Philadelphia, Pennsylvania $44.9M AUM 24.87% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
ZCA
Zeke Capital Advisors Berwyn, Pennsylvania $1.53B AUM 17.37% 1-Year Est. Return
WCM
Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return

Penserra Capital Management's URGN Position: Q4 2021 in Review

Penserra Capital Management sold out of UroGen Pharma (URGN) in Q4 2021, closing a stake of 510 shares — an estimated $8K sold.

Penserra Capital Management first reported a position in URGN in Q3 2020 and held it in 5 quarters. The position peaked at $9K in Q1 2021. 77 funds tracked by Wall St. Rank hold URGN as of Q4 2021.

  • Penserra Capital Management reported no remaining UroGen Pharma position as of Q4 2021 after selling out during the quarter.
  • Penserra Capital Management sold 510 UroGen Pharma shares in Q4 2021, an estimated $8K.
  • Penserra Capital Management first reported a position in UroGen Pharma in Q3 2020 and held it in 5 quarters.
  • Penserra Capital Management's UroGen Pharma position peaked at $9K in Q1 2021.
  • 77 funds tracked by Wall St. Rank held UroGen Pharma as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.